Protagonist Therapeutics Q4 EPS $(0.48), Inline, Sales $5.65M Beat $3.12M Estimate
Protagonist Therapeutics Q4 EPS $(0.48), Inline, Sales $5.65M Beat $3.12M Estimate
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.48) per share which met the analyst consensus estimate. This is a 23.81 percent increase over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $5.65 million which beat the analyst consensus estimate of $3.12 million by 81.09 percent. This is a 107.80 percent increase over sales of $2.72 million the same period last year.
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.48) per share which met the analyst consensus estimate. This is a 23.81 percent increase over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $5.65 million which beat the analyst consensus estimate of $3.12 million by 81.09 percent. This is a 107.80 percent increase over sales of $2.72 million the same period last year.
主角治療公司(NASDAQ:PTGX)公佈季度虧損為每股0.48美元,符合分析師的普遍預期。這比去年同期每股虧損0.63美元增加了23.81%。該公司公佈季度銷售額為565萬美元,比分析師普遍預期的312萬美元高出81.09%。這比去年同期272萬美元的銷售額增長了107.80%。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧